Tom Woiwode

Tom Woiwode is a Managing Director with Versant Ventures and has been with the company since 2002. He has served in both operational and investment roles during that time. Tom was the start-up Chief Business Officer for Amira (sale), Synosia (sale) and Flexion (2014 IPO) and was the Chief Operating Officer of Okairos where he led the process that culminated in the acquisition by GlaxoSmithKline. Since being promoted to Managing Director in 2014, Tom has assumed the lead role in multiple investments including Crispr (2016 IPO), Audentes (2016 IPO), Annapurna (merged to form Adverum Biotechnologies), Gritstone Oncology (2018 IPO), Crinetics (2018 IPO), Jecure (sale), Therachon (sale), Anokion, Vividion, Tempest Therapeutics, Aligos Therapeutics, CODA and Passage. He serves on a number of Versant portfolio company boards, including Adverum, Aligos, Anokion, CODA, Gritstone, Kanyos Bio, Tempest and Vividion.

Prior to joining Versant, Tom was a medicinal chemist at XenoPort, a start-up biotech company that completed an IPO in 2005.

Tom earned his PhD in chemistry from Stanford University.